The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Animal models in translational medicine: Validation and prediction
Open accessAbstract
Despite large investments in drug development, the overall success rate of drugs during clinical development remains low. One prominent explanation is flawed preclinical research, in which the use and outcome of animal models is pivotal to bridge the translational gap to the clinic. Therefore, the selection of a validated and predictive animal model is essential to address the clinical question. In this review, the current challenges and limitations of animal models are discussed, with a focus on the fit-for-purpose validation. Moreover, guidance is provided on the selection, design and conduct of an animal model, including the recommendation of assessing both efficacy and safety endpoints. In order to improve the clinical translation, the use of humanized mouse models and preclinical applications of clinical features are discussed. On top, the translational value of animal models could be further enhanced when combined with emerging alternative translational approaches. Focal points: • Bedside Animal models are essential for translation of drug findings from bench to bedside. Hence, critical evaluation of the face and predictive validity of these models is important. Reversely, clinical bedside findings that were not predicted by animal testing should be back translated and used to refine the animal models. • Benchside Proper design, execution and reporting of animal model results help to make preclinical data more reproducible and translatable to the clinic. • Industry Design of an animal model strategy is part of the translational plan rather than (a) single experiment(s). Data from animal models are essential in predicting the clinical outcome for a specific drug in development. • Community Review, standardization and refinement of animal models by disease expert groups helps to improve rigor of animal model testing. It is important that the applied animal models are validated fit-for-purpose according to stringent criteria and reproducible. • Governments As during drug development fit-for-purpose animal models are key for success in clinical translation, financial investments and support from the government to develop, optimize, validate and run such translation tools are important. Over time, this will be of benefit for patients and healthcare institutions. • Regulatory agencies Preclinical testing of a drug in an animal model is not a prerequisite for regulatory agencies before entering clinical trials, but does unquestionably provide valuable data on the expected clinical performance of the drug. Hence, testing in animal models is largely recommended from both a business and patient perspective. In addition, inclusion of safety parameters in animal models will help to build the required safety data package of drugs in development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Genetics of Mouse Behavior: Interactions with Laboratory Environment
Crabbe, J. C., Wahlsten, D., & Dudek, B. C. (1999) · Science · doi:10.1126/science.284.5420.1670 · Cited by 1,666
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Humanized mice for immune system investigation: progress, promise and challenges
Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V., & Greiner, D. L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3311 · Cited by 979
Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2012) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2012.02.010 · Cited by 728
Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
Siolas, D., & Hannon, G. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1069 · Cited by 669
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Different data from different labs: Lessons from studies of gene–environment interaction
Wahlsten, D., Metten, P., Phillips, T. J., Boehm, S. L., Burkhart‐Kasch, S., Dorow, J., Doerksen, S., Downing, C., Fogarty, J., Rodd‐Henricks, K., et al. (2003) · Journal of Neurobiology · doi:10.1002/neu.10173 · Cited by 495
Phase III and submission failures: 2007–2010
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Hidalgo, M., Bruckheimer, E., Rajeshkumar, N. V., Garrido-Laguna, I., De Oliveira, E., Rubio-Viqueira, B., Strawn, S., Wick, M. J., Martell, J., & Sidransky, D. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0233 · Cited by 406
Shultz, L. D., Saito, Y., Najima, Y., Tanaka, S., Ochi, T., Tomizawa, M., Doi, T., Sone, A., Suzuki, N., Fujiwara, H., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000475107 · Cited by 366
Current advances in humanized mouse models
Ito, R., Takahashi, T., Katano, I., & Ito, M. (2012) · Cellular & Molecular Immunology · doi:10.1038/cmi.2012.2 · Cited by 349
Kerbel, R. S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.213 · Cited by 326
Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., Mistry, Y., Dilger, P., Liefooghe, E., Cludts, I., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3325 · Cited by 316
Clonogenic assay with established human tumour xenografts
Fiebig, H. H., Maier, A., & Burger, A. M. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.009 · Cited by 291
Rice, A. S. C., Cimino-Brown, D., Eisenach, J. C., Kontinen, V. K., Lacroix-Fralish, M. L., Machin, I., Mogil, J. S., & Stöhr, T. (2008) · Pain · doi:10.1016/j.pain.2008.08.017 · Cited by 290
Self-citationTGN1412: From Discovery to Disaster
Attarwala, H. (2010) · Journal of Young Pharmacists · doi:10.4103/0975-1483.66810 · Cited by 253 · cited 1×
“One potential reason that might have contributed to this discrepancy is the fact that the antibody caused the activation of memory T-cells in the human volunteers, but less so in nonhuman primates despite a near 100% sequence identity of the target [7].”
BackgroundHuman Experimental Pain Models for Assessing the Therapeutic Efficacy of Analgesic Drugs
Olesen, A. E., Andresen, T., Staahl, C., & Drewes, A. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005447 · Cited by 239
Danner, R., Chaudhari, S. N., Rosenberger, J., Surls, J., Richie, T. L., Brumeanu, T.-D., & Casares, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019826 · Cited by 206
Villenave, R., Thavagnanam, S., Sarlang, S., Parker, J., Douglas, I., Skibinski, G., Heaney, L. G., McKaigue, J. P., Coyle, P. V., Shields, M. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110203109 · Cited by 205
Abate-Daga, D., Lagisetty, K. H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., Burns, W. R., Miermont, A. M., Teper, Y., Rudloff, U., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.209 · Cited by 191
Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Weroha, S. J., Becker, M. A., Enderica-Gonzalez, S., Harrington, S. C., Oberg, A. L., Maurer, M. J., Perkins, S. E., AlHilli, M., Butler, K. A., McKinstry, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2611 · Cited by 189
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy
Bouchlaka, M. N., Sckisel, G. D., Chen, M., Mirsoian, A., Zamora, A. E., Maverakis, E., Wilkins, D. E. C., Alderson, K. L., Hsiao, H.-H., Weiss, J. M., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131219 · Cited by 160
Richter, S. H., Garner, J. P., Zipser, B., Lewejohann, L., Sachser, N., Touma, C., Schindler, B., Chourbaji, S., Brandwein, C., Gass, P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016461 · Cited by 150
Brown, D. C., Boston, R. C., Coyne, J. C., & Farrar, J. T. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00513.x · Cited by 138
Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
Weyer, C., Gautier, J. F., & Danforth, E. (1999) · PubMed · Cited by 126
Moro, M., Bertolini, G., Tortoreto, M., Pastorino, U., Sozzi, G., & Roz, L. (2012) · BioMed Research International · doi:10.1155/2012/568567 · Cited by 105
Zhou, Q., Facciponte, J. G., Jin, M., Shen, Q., & Lin, Q. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.10.015 · Cited by 99
Human experimental pain models in drug development: translational pain research.
Arendt‐Nielsen, L., Curatolo, M., & Drewes, A. M. (2007) · PubMed · Cited by 92
Pitts, T. M., Tan, A. C., Kulikowski, G. N., Tentler, J. J., Brown, A. M., Flanigan, S. A., Leong, S., Coldren, C. D., Hirsch, F. R., Varella‐Garcia, M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3191 · Cited by 73
Strategies to optimize the validity of disease models in the drug discovery process
Sams-Dodd, F. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.005 · Cited by 60 · cited 2×
“[17] F. Sams-Dodd, Strategies to optimize the validity of disease models in the drug discovery process, Drug Discov.”
MethodPerinatal Lamb Model of Respiratory Syncytial Virus (RSV) Infection
Derscheid, R. J., & Ackermann, M. R. (2012) · Viruses · doi:10.3390/v4102359 · Cited by 59
Mechanistic systems modeling to guide drug discovery and development
Schmidt, B. J., Papin, J. A., & Musante, C. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.09.003 · Cited by 59
Lamberty, Y., Margineanu, D. G., & Klitgaard, H. (2000) · Epilepsy & Behavior · doi:10.1006/ebeh.2000.0098 · Cited by 58
Hooijmans, C. R., de Vries, R. B. M., Leenaars, M., Curfs, J. H. A. J., & Ritskes-Hoitinga, M. J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01128.x · Cited by 57
Quantitative systems pharmacology as an extension of PK/PD modeling in CNS research and development
Geerts, H., Spiros, Ä., Roberts, P., & Carr, R. A. (2013) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-013-9297-1 · Cited by 47
Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
Konstantinopoulos, P. A., & Matulonis, U. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00296 · Cited by 42
Application of a Systems Biology Approach to Skin Allergy Risk Assessment
Maxwell, G., & Mackay, C. D. A. (2008) · Alternatives to Laboratory Animals · doi:10.1177/026119290803600510 · Cited by 37
TGN1412: ScrutiniZing preclinical trials of antibody- based medicines
Hansen, S., & Leslie, R. G. Q. (2006) · Nature · doi:10.1038/441282a · Cited by 32
Singh, M., Singh, P., Vaira, D., Amand, M., Rahmouni, S., & Moutschen, M. P. (2014) · Immunology · doi:10.1111/imm.12246 · Cited by 22
Cited by
In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform
Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., & Searson, P. C. (2016) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00012 · Cited by 754
Molecularly Imprinted Polymers: Antibody Mimics for Bioimaging and Therapy
Haupt, K., Medina Rangel, P. X., & Bui, B. T. S. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00428 · Cited by 561
Löscher, W. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2222-z · Cited by 367
Shared molecular and cellular mechanisms of premature ageing and ageing-associated diseases
Kubben, N., & Misteli, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.68 · Cited by 320
Jeong, S.-Y., Lee, J.-H., Shin, Y., Chung, S., & Kuh, H.-J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159013 · Cited by 287
Metadata
- Authors
- Denayer, T., Stöhr, T., & Roy, M. V.
- Venue
- European Journal of Molecular & Clinical Medicine
- Published
- 2014-08-27
- Volume
- 2
- Issue
- 1
- Pages
- 5
- ISSN
- 2515-8260 (ISSN-L)
- OpenAlex
- W2000053231
- Cited by
- 448
- References
- 41
- FWCI
- 28.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.